IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: ideayabio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2026 | $50.00 | Buy | UBS |
| 11/24/2025 | Buy | Truist | |
| 9/18/2025 | $50.00 | Buy | Guggenheim |
| 9/4/2025 | $40.00 | Overweight | Barclays |
| 9/4/2025 | $41.00 | Mkt Outperform | Citizens JMP |
| 7/22/2025 | Buy | TD Cowen | |
| 7/10/2025 | $25.00 | Neutral | Goldman |
| 6/26/2025 | $44.00 | Overweight | Wells Fargo |
| 11/18/2024 | $51.00 | Overweight | Stephens |
| 11/5/2024 | $27.00 | Outperform → Market Perform | Leerink Partners |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
3 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
Fastest customizable press release news feed in the world
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinomaIDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the studyMTAP-deletion is estimated to occur in up to 40% of PDACSOUTH SAN FRANCISCO, Calif., June 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration
Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs. 3.1 months, HR: 0.42, 58% reduction in risk of disease progressionSignificantly improved ORR (37.1% vs 5.8%) and DCR (73.3% vs. 31.1%) by BICR vs. ICT, where ~77% were treated with ipilimumab + nivolumabOS not yet mature but early trend favoring the darovasertib combination; targeting to provide the next update as part of the pre-specified interim analysis Manageable safety profile consistent with prior results, with a low rate of TR-SAE (9.2%) and discontinuations due to TRAEs for darovasertib (2.5%) and crizotinib
SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 28, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 221,000 shares of the Company's common stock to six newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule
SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global Healthcare Conference. 2026 Jefferies Global Healthcare ConferenceWednesday, June 3rd, 2026 at 7:35 AM ETFireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, BiotechnologyAI Panel at the 2026 Jefferies Global Healthcare C
Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has every quality a drug developer wants. In practice, three B7-H3-targeting antibody-drug conjugates have entered the clinic, and none have yet been approved.[1] That is
Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell engager just entered the clinic SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy ti
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCOIDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2 2026Clinical updates from Phase 2 OptimUM-01 trial in HLA*A2-positive mUM, Phase 2 OptimUM-09 in neoadjuvant primary UM and Phase 1/2 trials with IDE849 (DLL3 TOP1 ADC) and IDE034 (B7H3/PTK7 bispecific TOP1 ADC) planned for H2 2026Initiation of registrational trial for IDE849 monotherapy in DLL3-positive solid tumors planned by year-end 2026; Phase 1 combination cohort of IDE892 (PRMT5) + IDE397 (MAT2A
SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 30, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 237,800 shares of the Company's common stock to five newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Ru
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and will be presented in a late-breaking oral presentation at ASCO 2026IDEAYA to initiate the RTOR submission process with the first pre-submission in May, with completion of the NDA filing expected in H2 '26SOUTH SAN FRANCISCO, Calif., April 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, today announced that the U.S. Food and Drug Administration (FDA) has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib (darovasertib combination) for patients with first line (1L) HLA*A2-negative metastatic uve
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-June 2 in Chicago, Illinois. The presentation will include detail and additional data from OptimUM-02 that were not disclosed with the company's topline release.
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
424B5 - IDEAYA Biosciences, Inc. (0001676725) (Filer)
S-3ASR - IDEAYA Biosciences, Inc. (0001676725) (Filer)
10-Q - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
DEFA14A - IDEAYA Biosciences, Inc. (0001676725) (Filer)
DEF 14A - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
UBS resumed coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00
Truist initiated coverage of IDEAYA Biosciences with a rating of Buy
Guggenheim initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00
Barclays initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $40.00
Citizens JMP initiated coverage of IDEAYA Biosciences with a rating of Mkt Outperform and set a new price target of $41.00
TD Cowen initiated coverage of IDEAYA Biosciences with a rating of Buy
Goldman resumed coverage of IDEAYA Biosciences with a rating of Neutral and set a new price target of $25.00
Wells Fargo initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $44.00
Stephens initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $51.00
Leerink Partners downgraded IDEAYA Biosciences from Outperform to Market Perform and set a new price target of $27.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
Live finance-specific insights
Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, 0.59; p-value: <0.0001)Secondary endpoint of ORR by BICR was 37.1% for the darovasertib combination versus 5.8% for ICT (p-value: <0.0001), including 5 complete responses in the darovasertib combination armDarovasertib combination showed an early trend in improvement for OS versus ICTWell-tolerated, with manageable safety profile consistent with previously reported AEsNDA submission planned for H2'26 to support U.S. accelerated approval filing. Full data from OptimUM-02 to be presented at major
SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma. The call will include members of IDEAYA's management joined by a distinguished key opinion leader.
Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.
~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-
Confirmed overall response rate (ORR) of 45%, disease control rate (DCR) of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational trial in Q2 2023 in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approvalConfirmed overall response rate (ORR) of 30%, disease control rate (DCR) of 87% and median PFS of ~7 months in 63 evaluable Any-Line MUM patientsConfirmed overall response rate (ORR) of 35%, disease control rate (DCR) of 100% and median PFS of ~11 months in 20 evaluable Hepatic-Only MUM patientsHistorical % ORR and median PFS by other therapies in MUM have been low, rang
Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patientsTumor shrinkage observed in 31 of 35 (89%) Any-Line MUM patientsMedian PFS not yet reached and >5 months in evaluable First-Line MUM patients; observed median PFS of ~5 months in evaluable Any-Line MUM patientsHistorical % ORR and median PFS by other therapies in MUM have been low, ranging from ~0% to 5% ORR and ~2 to 3 months median PFSProof-of-concept for use in (neo)adjuvant UM with tumor shrinkage in 5 of 5 ocular lesions, including reductions of ~-74% and -67%, each with improved visual symptomsTotal UM and MUM annual incidence in
SAN FRANCISCO, May 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in May 2022. 2022 JP Morgan Conference Call SeriesMonday, May 16 at 10:00am ETFireside chat with Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, hosted by Anupam Rama, Managing Director US SMID Biotechnology Equity Research Virtual Guggenheim Synthetic Lethality Day Monday, May 16 at 12:00pm ETFireside
Observed preclinical complete suppression (~95-100%) of tumor SDMA in multiple MTAP-deleted patient derived xenograft (PDX) models across indications Interim IDE397 clinical data demonstrates robust plasma pharmacodynamic modulation, exceeding target of >60% reduction of plasma SAM across all evaluated cohorts Observed clinical exposure-dependent reduction of tumor pharmacodynamic biomarker SDMA in target tumor types, including 95% reduction of tumor SDMA No drug-related Serious Adverse Events (SAEs) observed through Cohort 5 Enrolling into Cohort 6 of the dose escalation Phase 1 evaluating IDE397; have not yet determined the maximum tolerated dose (MTD) through Cohort 5 Targeting initiation
SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced plans to issue a pre-market press release and host an Investor Webcast on Tuesday, March 15, 2022 to discuss interim clinical data for IDE397, a potential best-in-class MAT2A inhibitor being evaluated in a Phase 1 Clinical Trial (NCT 04794699) in patients having tumors with MTAP deletion. IDEAYA will host a conference call and webcast
This live feed shows all institutional transactions in real time.
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
Live Leadership Updates
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCOIDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2 2026Clinical updates from Phase 2 OptimUM-01 trial in HLA*A2-positive mUM, Phase 2 OptimUM-09 in neoadjuvant primary UM and Phase 1/2 trials with IDE849 (DLL3 TOP1 ADC) and IDE034 (B7H3/PTK7 bispecific TOP1 ADC) planned for H2 2026Initiation of registrational trial for IDE849 monotherapy in DLL3-positive solid tumors planned by year-end 2026; Phase 1 combination cohort of IDE892 (PRMT5) + IDE397 (MAT2A
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's emerging oncology pipeline and play a crucial role in guiding the company's long-term R&D strategy. Dr. Ross joins IDEAYA from AbbVie, where she served as Vice President, Head of Early Oncology R&D and Site Head for the Bay Area.
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer. Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May.
Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & CompanySOUTH SAN FRANCISCO, Calif., May 28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Daniel A. Simon, will join the company as its Chief Business Officer in August 2024. "We are thrilled to welcome Daniel to IDEAYA Biosciences. His extensive expertise in corporate strategy
- Dr. Karlene Cimprich, Ph.D. (Stanford University), is a leading scientist in replication stress mechanisms and regulation of DNA Damage Repair pathways - Dr. Kornelia Polyak, M.D., Ph.D. (DFCI, Harvard University) is a renowned physician-scientist focused on breast cancer clinical management and tumor biology SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Dr. Karlene Cimprich, Ph.D., and Dr. Kornelia Polyak, M.D., Ph.D., to its Scientific Advisory Board.
Former Senior Vice President and Head of Early Oncology Development and Clinical Research at Pfizer will lead IDEAYA's clinical development efforts as Chief Medical OfficerOver twenty-five years of experience in clinical development and translational research, including at leading pharmaceutical companies and major research institutionsSOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Darrin M. Beaupre, M.D., Ph.D., has joined the company as its Chief Medical Officer, effective November 21, 2022.
- Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Laboratories SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors. Dr. Mackey brings over 30 years of life sciences research, development and operational experience to IDEAYA. As Senior